Press Releases + News

Date Title and Summary View
Toggle Summary Galectin Therapeutics Receives US Patent for Second Drug Class to Treat Chronic Liver Disease with Fibrosis (Scarring) and Cirrhosis View HTML
Toggle Summary Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 View HTML
Toggle Summary Galectin Therapeutics Reports Third Quarter 2012 Financial Results View HTML
Toggle Summary Galectin Therapeutics to Present New Data on the Treatment of Fatty Liver Disease and Fibrosis at AASLD 2012 View HTML
Toggle Summary Galectin Therapeutics Hosted International Conference on Galectins and Disease
--Proceedings from the Conference to be Published in Early 2013--
View HTML
Toggle Summary Galectin Therapeutics Announces Relocation of Corporate Headquarters to Atlanta, GA View HTML
Toggle Summary Galectin Therapeutics Appoints Harold H. Shlevin, PhD, Bioscience Industry Executive, as Chief Operating Officer View HTML
Toggle Summary Galectin Therapeutics to Present at the RedChip Small-Cap Equities Virtual Conference View HTML
Toggle Summary Galectin Therapeutics Reports Second Quarter 2012 Financial Results View HTML
Toggle Summary Galectin Therapeutics Planning Clinical Trials for Early 2013 to Treat Fatty Liver Disease with Advanced Fibrosis After Recent FDA Meeting View HTML